Related Experiment Videos
Complement fragment C3a in plasma of asphyxiated neonates
L Schrod1, G Frauendienst-Egger, H B von Stockhausen
1Department of Paediatrics, University of Würzburg, Federal Republic of Germany.
European Journal of Pediatrics
|September 1, 1992
Summary
Elevated C3a levels in newborns with respiratory distress syndrome may indicate a risk for developing adult respiratory distress syndrome (ARDS). Higher C3a concentrations were observed in infants experiencing asphyxia, suggesting C3a as a potential diagnostic marker.
Area of Science:
- Neonatal Medicine
- Immunology
- Critical Care
Background:
- Adult studies link elevated C3a to adult respiratory distress syndrome (ARDS).
- Neonatal ARDS diagnosis lacks reliable indicators.
- Shock is a primary risk factor for neonatal ARDS.
Purpose of the Study:
- To investigate C3a plasma levels in neonates with respiratory distress syndrome.
- To assess the correlation between C3a levels and neonatal ARDS development.
- To evaluate C3a as a potential diagnostic marker for neonatal ARDS.
Main Methods:
- Plasma C3a levels were measured using ELISA in 30 ventilated neonates with respiratory distress syndrome.
- Measurements were taken within 24 hours of birth or 6-24 hours after asphyxia/shock.
- C3a levels were compared between asphyxia and control groups.
Main Results:
- Peak C3a levels were significantly higher in the asphyxia group (mean 388 ng/ml) compared to controls (mean 153 ng/ml; P < 0.001).
- In neonates with suspected ARDS, a C3a increase between days 2-8 correlated with a fatal outcome.
- C3a levels ranged from 57 to 1000 ng/ml.
Conclusions:
- C3a may serve as a valuable indicator for diagnosing ARDS in neonates.
- Elevated C3a levels are associated with increased risk and severity of neonatal respiratory distress.
- Further research is warranted to establish C3a as a standard diagnostic tool for neonatal ARDS.